GlycoEra appoints Andrea Matthews, a former Astria dealmaker, as chief business officer. The Swiss-US biotech specializes in protein degrader therapies and is positioning its lead autoimmune candidate for potential partnerships and investor discussions.
GlycoEra AG has hired Andrea Matthews as Chief Business Officer to drive its expansion. The biotechnology firm specializes in extracellular protein degraders for autoimmune disease treatments. This leadership addition aims to accelerate the company’s growth trajectory in drug development.
GlycoEra appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to lead its precision immune degrader pipeline. Dr. Duda brings specialized expertise in rare and immune-mediated diseases, supporting GlycoEra’s focus on targeted therapeutic approaches.
GlycoEra secures **$130 million in Series B funding** to accelerate development of its **precision degraders targeting IgG4 antibodies**, a subtype linked to autoimmune diseases. The company focuses on therapies designed to neutralize specific immune pathways. Clinical progress will now advance faster with the additional capital.
